Latest Diabetes management Stories

FARMINGTON, June 12, 2012 /PRNewswire-iReach/ -- Non-insulin dependent (Type 2) diabetes accounts for 90% of all diagnosed cases of diabetes. The leading non-insulin antidiabetic Actos will lose its patent exclusivity in August 2012, offering significant market opportunities for competing generics. Having accurate market data and analysis will be essential to companies seeking to compete in this space. With premium market research from the world's leading publishers, Global...

PHILADELPHIA, June 12, 2012 /PRNewswire/ -- One in four people with type 2 diabetes missed or did not dose their long-acting (basal) insulin correctly in the previous 30 days, according to a new global survey funded by Novo Nordisk. The GAPP2(TM) (Global Attitudes of Patients and Physicians) survey also found that more than a third experienced a self-treated low blood sugar event called hypoglycemia. The data was presented at the late-breaking poster session of the 72nd Scientific...

PHILADELPHIA, June 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System. The data were presented during an oral...

Researchers at Joslin Diabetes Center hope to use experiences of people with long-term type 1 diabetes to benefit others Researchers at Joslin Diabetes Center, supported by JDRF, have completed a study of 158 people who have lived with type 1 diabetes (T1D) for 50 years or more with eye examinations at Joslin over many decades of follow-up, and have concluded that a high proportion of this unique group of patients developed little to no diabetic eye disease over time. The study focuses on...

SAN JOSE, Calif., June 11, 2012 /PRNewswire/ -- C8 MediSensors, Inc. (www.c8medisensors.com), the leading company developing noninvasive continuous glucose monitoring for people with diabetes, announced today that it has raised an incremental $19 million through the sale of Preferred C-1 stock. (Logo: http://photos.prnewswire.com/prnh/20120406/AQ83655LOGO) This additional round of funding helps C8 MediSensors prepare for its upcoming product launch in Europe. C8 MediSensors'...

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority (A1C is a measure of average blood sugar over three months). Further, data from the study indicated that rHuPH20 reduced postprandial glycemic...

Those with pre-diabetes can avoid getting diabetes People with pre-diabetes are significantly less likely to develop diabetes if their blood glucose levels are normalized in time, according to new research by the Colorado School of Public Health and the University of Colorado School of Medicine. The study was recently published in The Lancet. "The importance of this analysis is clear," said Leigh Perreault, MD, a researcher with the CU School of Medicine and the Colorado School of...

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced results from two Phase II studies of their investigational novel basal insulin analog, LY2605541. Results of the type 1 diabetes study showed that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than insulin glargine. In the type 2 diabetes study, the primary measure showed that LY2605541 and insulin glargine had...

PARIS, France, June 11, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention), which showed that Lantus® (insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period. Results also showed that insulin glargine delayed progression from pre-diabetes to type 2...

TARRYTOWN, N.Y., June 11, 2012 /PRNewswire/ -- A new blood glucose monitoring (BGM) system from Bayer, the CONTOUR® Next EZ meter and CONTOUR® Next test strips, proved easy to use and highly accurate in the hands of intended users -- patients and their healthcare professionals (HCPs) - according to a clinical study presented at the American Diabetes Association 72nd Scientific Sessions in Philadelphia, PA. (Logo: http://photos.prnewswire.com/prnh/20120418/NY90105LOGO ) Dr....